HERBERT FRITSCHE received the 2015 Abbott Award from the International Society of Oncology and Biomarkers for contributions to the field of basic or clinical oncology.
CARLOS ARTEAGA and FREDERICK ALT were named the winners of the 2015 Prize for Scientific Excellence by the American-Italian Cancer Foundation.
The 70th annual Lasker Awards went to: Evelyn Witkin and Stephen Elledge for basic medical research; James Allison for clinical research; and Doctors Without Borders for public service.
The U.S. Government Accountability Office said it would investigate the controversy stemming from wide use of power morcellators, gynecological devices now known to spread undetected cancers during hysterectomies and myomectomies.
The Health Resources and Services Administration issued the long-awaited “mega-rule” intended to define who qualifies for deep discounts on drug prices under the federal 340B program.
After a courtroom victory against Amgen Inc. this summer, the last of the obstacles was removed for the first biosimilar agent—a white blood cell growth factor—to enter the U.S. market.
JEFFREY LITWIN was named editor-in-chief of the Journal of Clinical Trial Results.
The European Commission granted a marketing authorization for Unituxin (dinutuximab) for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation. Unituxin is administered in combination with granulocyte-macrophage colony-stimulating factor,... […]
The TELESTAR trial demonstrated significant benefits in evaluating oral telotristat etiprate in the treatment of cancer patients with carcinoid syndrome, and met its primary endpoint.
The latest overall survival analysis of the HEAT Study, which is evaluating ThermoDox and radiofrequency ablation in hepatocellular carcinoma, showed that a subgroup of patients demonstrated an average 58 percent improvement in overall survival.
